Neuphoria Therapeutics Inc. Common Stock (NEUP)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. Neuphoria is a clinical-stage biotech with one employee, so it fails the first test: there is no durable earnings stream and no moat I can identify. In FY2026, the year ended 2026-06-30, filed figures show revenue of $1.2 million, a net loss of $13.5 million, and diluted EPS of -$3.06. That followed FY2025, ended 2025-06-30, with revenue of $15.6 million, a net loss of $369,632, and diluted EPS of -$0.23; FY2024, ended 2024-06-30, had revenue n/a, a net loss of $15.5 million, and diluted EPS of -$18.62. The Lynch category is none because the company lost money in each of the last four years. At the 2026-10-13 close of $3.39, FairStock calculates a market cap of $18.3 million, P/B of 0.62, P/E of -1.11, and FCF yield of -67.3%. A trailing FCF loss of $12.4 million means the enterprise consumes cash; FairStock calculates an Altman Z-Score of -5.81 and a Piotroski F-Score of 3/9. The balance sheet has no debt (D/E 0.00), which helps, but book value can shrink with losses. FairStock also calculates ROE of -61.70% and ROCE of -19.66%, confirming poor returns. This is a speculative drug-development option, not a Graham-style bargain, and the low price relative to book may be compensation for binary risk rather than safety.

In plain English: Neuphoria Therapeutics is a small early-stage drug developer working on treatments for serious brain and nervous-system conditions. It is not yet profitable, has lost money for years, and burns cash, so the business looks weak. At the 2026-10-13 close of $3.39, the stock trades below the value of its recorded net assets, but that does not make it a safe bargain because there are no steady earnings.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer